Objective

Antibody Drug Conjugates (ADCs) are an established and successful approach to treating cancer but despite decades of R&D there is only one approved for a solid tumour indication. The reasons for this include higher failure rates of ADCs in solid tumours, fewer ideal targets and conflicting commercial priorities between solid and haematological cancers. Antikor has re-invented the ADC area by designing smaller antibody ‘fragment' formats (FDCs) that can penetrate solid tumours more effectively than ADCs, eliminate from the body more rapidly leading to better tolerability but still retain high enough potency by virtue of a high drug:antibody ratio (DAR). Exemplifying the technology with the HER2 target, Antikor will illustrate all the beneficial features of its technology and give an update on its current R&D program to discover and develop a lead FDC candidate for gastro-intestinal cancer.